VERAXA Biotech AG (NASDAQ: VRXA) is promoting partnering opportunities for its proprietary BiTAC-ADC and BiTAC-TCE technology platforms ahead of the BIO International Convention, which will be held June 22-25, 2026, in San Diego. The company recently reported new proof-of-concept data supporting its BiTAC-ADC platform, which is designed to improve cancer treatment precision through tumor-restricted activation of therapeutic agents while minimizing off-target toxicity.
According to VERAXA, these findings, along with previously presented BiTAC-TCE data unveiled at the American Association for Cancer Research Annual Meeting in April 2026, support the potential of two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both technologies at the BIO International Convention.
The BiTAC-ADC platform represents a novel approach to antibody-drug conjugates, aiming to restrict the activity of the therapeutic agent to the tumor microenvironment. This could potentially reduce systemic side effects and improve the therapeutic index. The BiTAC-TCE platform focuses on bispecific T cell engagers, designed to redirect T cells to kill cancer cells more effectively.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a pipeline of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats.
For more details, the full press release is available at https://ibn.fm/r8zEz. Additional information about VERAXA Biotech can be found in its newsroom at http://ibn.fm/VRXA.
